<DOC>
	<DOC>NCT02180165</DOC>
	<brief_summary>The primary objective of this study is to assess and compare the safety of posaconazole with voriconazole in Japanese participants with Aspergillosis.</brief_summary>
	<brief_title>Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Body weight &gt;=45 kg Can be treated by taking tablet orally or intravenous (IV) formulation via central vein Female has a negative pregnancy test Female of nonchildbearing potential; or if of childbearing potential, agrees to use proper combination of barrier method of birth control Met screening criteria for either Invasive Aspergillosis, Chronic pulmonary aspergillosis, Zygomycosis or Fusariosis. Has a fungal infection other than Aspergillus any species (spp.) Zygomycetes (including Mucor spp.) and Fusarium spp. infection Has allergic bronchopulmonary aspergillosis, allergic sinusitis of aspergillosis, or aspergillosis of the eye Has longterm inactive aspergilloma not expected to respond to investigational product Is not expected to survive study duration Has an underlying disease, complication and systemic condition which makes it difficult to evaluate effect of study drug Has received, or continues to receive any systemic antifungal therapy, and cannot discontinue this treatment; but if fungal infection does not improve, can switch to study drug Is expected to need prohibited medications Has received posaconazole, has received voriconazole for this infection in the past and has deepseated fungal infection that has not responded to this treatment, has intolerance for azole antifungal treatments, or is receiving antifungal combination therapy for chronic pulmonary aspergillosis Has known hypersensitivity to any medication Has history of either Torsade de Pointes, myocardial infarction within previous 90 days, has congenital or acquired long QT interval syndrome, or unstable cardiac arrhythmia Has significant liver dysfunction Has liver cirrhosis or cholestasis Has renal insufficiency Has a known hereditary problem of either galactose intolerance, Lapp lactase deficiency, or glucosegalactose malabsorption Has acute symptomatic pancreatitis within 6 months of study entry or chronic pancreatitis Has an active skin lesion consistent with squamous cell carcinoma or melanoma, or within prior 5 years a history of malignant melanoma Has known or suspected Gilbert's disease Female is pregnant, or nursing, or intends to become pregnant within 14 days after end of study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>